These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28452143)

  • 1. ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus.
    Jain MR; Joharapurkar AA; Kshirsagar SG; Patel VJ; Bahekar RH; Patel HV; Jadav PA; Patel PR; Desai RC
    Br J Pharmacol; 2017 Jul; 174(14):2346-2357. PubMed ID: 28452143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor.
    Jain MR; Joharapurkar AA; Bahekar RH; Patel H; Jadav P; Kshirsagar SG; Patel VJ; Patel KN; Ramanathan VK; Patel PR; Desai RC
    J Diabetes; 2015 Sep; 7(5):708-17. PubMed ID: 25327540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Patel BD; Bhadada SV; Ghate MD
    Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
    Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study.
    Li Q; Meng L; Zhou S; Deng X; Wang N; Ji Y; Peng Y; Xing J; Yao G
    Eur J Med Chem; 2019 Oct; 180():509-523. PubMed ID: 31336309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li Q; Deng X; Jiang N; Meng L; Xing J; Jiang W; Xu Y
    Eur J Med Chem; 2021 Dec; 225():113765. PubMed ID: 34399391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
    Someya Y; Tahara A; Nakano R; Matsuyama-Yokono A; Nagase I; Fukunaga Y; Takasu T; Hayakawa M; Shibasaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2008 May; 377(3):209-17. PubMed ID: 18398600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model.
    Davis JA; Kumar PS; Singh S; Surender A; Roy S; Khanna V; Sethi S; Pal C; Sharma L; Benjamin B; Mittra S; Sattigeri J; Bansal VS
    Indian J Pharmacol; 2012; 44(6):759-64. PubMed ID: 23248408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors.
    Li N; Wang LJ; Jiang B; Guo SJ; Li XQ; Chen XC; Luo J; Li C; Wang Y; Shi DY
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2131-2135. PubMed ID: 29773502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity.
    Yeh KC; Yeh TK; Huang CY; Hu CB; Wang MH; Huang YW; Chou LH; Ho HH; Song JS; Hsu T; Jiaang WT; Chao YS; Chen CT
    Life Sci; 2021 Aug; 278():119574. PubMed ID: 33961850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
    Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
    J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Pharmacol Rep; 2009; 61(5):899-908. PubMed ID: 19904014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.
    Zhang C; Ye F; Wang J; He P; Lei M; Huang L; Huang A; Tang P; Lin H; Liao Y; Liang Y; Ni J; Yan P
    J Med Chem; 2020 Jul; 63(13):7108-7126. PubMed ID: 32452679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of the benzamide fragment targeting the S
    Deng X; Wang N; Meng L; Zhou S; Huang J; Xing J; He L; Jiang W; Li Q
    Bioorg Chem; 2020 Jan; 94():103366. PubMed ID: 31640932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
    Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
    Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
    Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.